Trial Profile

Phase I Trial of Ruxolitinib Plus Fostamatinib for the Treatment of Steroid Refractory Chronic Graft Versus Host Disease

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 11 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Fostamatinib (Primary) ; Ruxolitinib (Primary)
Indications Graft-versus-host disease
Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Therapeutic Use

Most Recent Events

05 Jun 2025 Planned initiation date (Estimated date of first participant enrollement) changed from 1 May 2025 to 1 Jun 2025.
05 Jun 2025 Status changed from not yet recruiting to recruiting.
24 Jan 2025 Planned initiation date changed from 1 Nov 2024 to 1 May 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com